Skip to main content

Research News

Join WhatsApp Channel 

Regulatory Affairs Courses
  • Researchers have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves. The study was published in PLOS One.

    [adsense:336x280:8701650588]

  • A new study warns that if you often feel dizzy, faint or light-headed after getting up, these symptoms could indicate greater risk of developing brain disease such as Parkinson's or dementia, and even an increased risk of death. The findings appeared in the online issue of the journal Neurology.

  • New research suggests that some, but not all adults who have experienced sexual or physical abuse as children go on to develop long term depression, this could partly be due to their specific genetic make up. Researchers also found that the same gene variant that can make a person sad in one context, can trigger happiness in another context. The research was published in the British Journal of Psychiatry Open.

  • GE Healthcare announced that the US Drug Enforcement Administration (DEA) has removed the compound ioflupane I 123 from the schedules of the Controlled Substance Act, which has resulted in the descheduling of DaTscan™ (Ioflupane I 123 Injection). DaTscan is the FDA-approved imaging agent which provides an assessment of the integrity of the striatal dopaminergic system via the dopamine transporter to help physicians determine whether patients have essential tremor (ET) or a parkinsonian syndrome (PS) movement disorder such as Parkinson’s disease (PD). The action may help ensure that more healthcare providers and patients with a suspected PS or ET across the United States will have access to imaging with this agent.

    [adsense:336x280:8701650588]

  • If  you want to remain fit and healthy, try to go for frequent breaks from prolonged sitting at workplace or home. Researchers from King's College London have shown that increasing the levels of physical activity is likely to be much less effective at reducing prolonged sitting than directly attempting to decrease sitting time. The paper appeared in the journal Health Psychology Review.

  • A panel of experts from the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee discussed considerations to help ensure the continued safe and appropriate use of Essure® permanent birth control. While there was agreement among the Panel members that Essure is an important contraceptive option, the Panel provided input and guidance for the FDA and Bayer to consider. Based on information presented during this meeting, the Advisory Panel discussed a number of considerations including clinical research, patient education and counseling. The Panel also discussed training and certification of physicians; and post-procedural patient management including removal of the device.

Subscribe to Research News